STRATA Skin Sciences Files 8-K

TL;DR

STRATA Skin Sciences filed an 8-K on July 17, 2024, covering disclosures and financials.

AI Summary

On July 17, 2024, STRATA Skin Sciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC, is incorporated in Delaware and headquartered in Horsham, Pennsylvania.

Why It Matters

This 8-K filing indicates routine corporate reporting, including financial statements and disclosures, which are important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report for disclosures and exhibits, not indicating any immediate material adverse events.

Key Numbers

• 000-51481 — SEC File Number (Identifies the company's filing with the SEC.)
• 13-3986004 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• MELA SCIENCES, INC. (company) — Former Company Name
• ELECTRO OPTICAL SCIENCES INC (company) — Former Company Name
• July 17, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Horsham, Pennsylvania (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ

Filing Documents

• ef20032529_8k.htm (8-K) — 29KB
• ef20032529_99-1.htm (EX-99.1) — 18KB
• image01.jpg (GRAPHIC) — 13KB
• 0001140361-24-033358.txt ( ) — 221KB
• sskn-20240717.xsd (EX-101.SCH) — 4KB
• sskn-20240717_lab.xml (EX-101.LAB) — 21KB
• sskn-20240717_pre.xml (EX-101.PRE) — 16KB
• ef20032529_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure. On July 17, 2024, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing the publication of a clinical study titled, "Advancing precision acne therapy using a photopneumatic device," in the July 11, 2024 issue of the Journal of Cosmetic and Laser Therapy . In the study, the Company's TheraClear X Acne Therapy System was shown to reduce lesions and associated skin redness with improvement in skin texture and pore size after one to three treatments with infrequent adverse effects, providing benefit as monotherapy and/or as an adjuvant. The ability to change pulse structure, pulse duration, vacuum pressure, and fluence (i.e., energy intensity) allowed for treatment that best matched skin type and acne therapy. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following press release is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be "filed": Exhibit No. Exhibit Description 99.1 Press release dated July 17, 2024, issued by Strata Skin Sciences, Inc. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: July 17, 2024 By: /s/ Christopher Lesovitz Christopher Lesovitz Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR